CYTO Innovation: What We Say and How We Say It Are the Most Powerful Tools We Have

Andrea Cossarizza is a Full Professor of Pathology and Immunology, Vice President of the Faculty of Medicine at the University of Modena and Reggio Emilia, and current Past President of ISAC. He has been studying the molecular and cellular basis of several diseases that involve the immune system for 35 years. He is currently at the forefront of the fight against COVID-19, and has provided the first contributions regarding the importance of cytometry in understanding the immune response to SARS-CoV-2. As of May 2020, he has published 332 papers on peer reviewed journal, has an H index of 79 and has received over 33,000 citations.

Pratip Chattopadhyay, PhD is an Associate Professor (Pathology) and founding Director of NYU Langone Health’s Precision Immunology Laboratory (PIL). His laboratory performs independent research in tumor immunology and provides cutting-edge immune monitoring services for a wide variety of biomedical disciplines (cancer, infectious disease, rheumatology). We use high parameter cytometry technologies, including 30-parameter flow cytometry and combined protein/mRNA analysis by RNA sequencing (molecular cytometry), to reveal biomarkers that predict patient outcomes, better understand disease pathogenesis, and inform rational design of combination drug therapies.

Dr. Nicole Poulton is the Director of the Center for Aquatic Cytometry, and a Research Scientist at Bigelow Laboratory for Ocean Sciences.  Nicole’s main research interests focus on phytoplankton and aquatic microbial ecology, including harmful algal blooms and the role of phytoplankton in the global carbon cycle.  Her research uses aquatic flow and imaging cytometry, single cell sorting and genomics to examine phytoplankton and bacterioplankton in the oceanic environment.   She has over 25 years of flow cytometric experience within the aquatic sciences. Nicole received her PhD in Biological Oceanography from the Massachusetts Institute of Technology and Woods Hole Oceanographic Institution.  She joined Bigelow Laboratory as a Research Scientist in 2008 and became the Director of the Center for Aquatic Cytometry in 2014.  Nicole is very active in education and outreach and is also an ISAC Shared Resource Laboratory Emerging Leader (2017-2021).

Jonni Moore, Ph.D. is a Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania, Scientific Director of the Abramson Cancer Center Flow Cytometry and Cell Sorting Shared Resource, and Emeritus Director, Founder, and currently Senior Advisor of the Clinical Flow Cytometry Laboratory at the Hospital of the University of Pennsylvania. She is currently the President of ISAC.  She received her PhD from Thomas Jefferson University in Philadelphia in Microbiology and completed a postdoc with Peter Nowell, MD at the University of Pennsylvania.

Dr. Holden’s area of expertise and interests are in advancing the commercialization of breakthrough developments in cancer cell biology, personalized biomarkers of disease progression and therapy together with the implementation of imaging cytometry systems for cell-based analyses. During her career she led multi-functional teams as Chief Strategic Marketing at Thorlabs, President and CEO of Compucyte Corporation, and Business Development Manager/Regional Director at Chiron Diagnostics. Today Elena leads development and commercialization of IDV products as President and CEO, Tomocube USA, Inc. and Chief Strategy Officer, TomoCube, South Korea. She is also an Associate Editor of the Cytometry Part A, the official journal of ISAC and a committee member of the SPIE/ Photonics West Quantitative Phase Imaging.

For over a decade, Genoa Ventures’ founder and managing director Dr. Jenny Rooke has been deploying capital at the frontiers of life sciences innovation, with a penchant for technology-fueled solutions and category-defying opportunities. Jenny got her start in venture at Fidelity Biosciences, a Cambridge-based healthcare VC, during their Fund I formation. Jenny then brought her unique toolkit of genetics domain expertise, strategic business acumen, and venture investing to the Gates Foundation, where she deployed and managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. She also played a key role in establishing the foundation’s investing function. In 2014, Dr. Rooke began independently investing under the brand 5 Prime Ventures, financing her investments using what has become the largest life sciences syndicate on AngelList, and one of the highest-performing AngelList syndicates of any sector. Jenny founded Genoa Ventures in 2018, building on the 5 Prime Ventures track record, in order to scale a proven, differentiated investing strategy, to ensure continued access to the very best deals, and to maximize portfolio returns

Ursula Errington is a former news correspondent and business news presenter for Sky News in the UK. During a broadcast career of more than a decade, she also worked for BBC regional news as a news anchor and Monocle 24 Radio as a breakfast presenter on the station’s flagship current affairs program. During her career as a journalist, Ursula worked on a huge variety of stories across domestic, foreign, political and business news, bringing her incisive style of interviewing to millions of viewers and listeners. She has interviewed two UK Prime Ministers and three Chancellors of the Exchequer, household name CEOs and countless academics, analysts, experts and members of the public with a story to tell. Today, Ursula runs Hard Truth Media Ltd and is a Special Communications Advisor to VIPs and C-Suite executives. She travels the world preparing them to deliver speeches, participate in panel discussions and conduct media interviews. Ursula is passionate about helping clients develop clear, authentic, audience-centric messages they can deliver with ease, because they truly believe in them.